申请人:Celltech Therapeutics, Limited
公开号:US06093696A1
公开(公告)日:2000-07-25
Tyrosine derivatives of formula (1) are described: ##STR1## in which R is (1) a group R.sup.1 X.sup.1 -- where R.sup.1 is an optionally substituted alkyl or aromatic group, and X.sup.1 is a covalent bond or a --(CH.sub.2).sub.n -- [where n is an integer 1 or 2], --C(O)--, --CH.sub.2 C(O)--, --NHC(O)--, --CH.sub.2 NHC(O)--, or --SO.sub.2 -- group, or (2) a group (Hal.sup.1).sub.3 CSO.sub.2 --, where Hal.sup.1 is a fluorine or chlorine atom; R.sup.2 and R.sup.3, which may be the same or different, is each a hydrogen or halogen atom or an alkyl, alkoxy, hydroxyl or nitro group; Alk is an alkylene chain; m is zero or an integer 1; R.sup.4 is a hydrogen atom or a methyl group; R.sup.5 is a group --(CH.sub.2).sub.p CO.sub.2 R.sup.8 where p is zero or an integer 1 and R.sup.8 is a hydrogen atom or an alkyl group; R.sup.6 is a hydrogen atom or an alkyl group; Y is a sulphur atom or a --S(O).sub.q -- group where q is an integer 1 or 2; X.sup.2 is a --C(O)--, --C(O)O--, --CONH-- or --S(O).sub.2 -- group; R.sup.7 is an optionally substituted alkyl group or an aryl or aralkyl group; and the salts, solvates and hydrates thereof. The compounds are able to inhibit the binding of .alpha..sub.4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
描述了化学式(1)的酪氨酸衍生物:##STR1##
其中,R为(1)R.sup.1 X.sup.1基团,其中R.sup.1为可选择取代的烷基或芳香基团,X.sup.1为共价键或--(CH.sub.2).sub.n--[其中n为整数1或2],--C(O)--,--CH.sub.2C(O)--,--NHC(O)--,--CH.sub.2NHC(O)--或--SO.sub.2--基团,或(2)(Hal.sup.1).sub.3CSO.sub.2--基团,其中Hal.sup.1为氟或氯原子;R.sup.2和R.sup.3,可以相同也可以不同,分别为氢或卤素原子或烷基,烷氧基,羟基或硝基基团;Alk为烷基链;m为零或整数1;R.sup.4为氢原子或甲基基团;R.sup.5为基团--(CH.sub.2).sub.pCO.sub.2R.sup.8,其中p为零或整数1,R.sup.8为氢原子或烷基基团;R.sup.6为氢原子或烷基基团;Y为硫原子或--S(O).sub.q--基团,其中q为整数1或2;X.sup.2为--C(O)--,--C(O)O--,--CONH--或--S(O).sub.2--基团;R.sup.7为可选择取代的烷基或芳基或芳基烷基团;以及其盐,溶剂化合物和水合物。这些化合物能够抑制α.sub.4整合素与其配体的结合,并用于预防和治疗免疫或炎症性疾病。